

NCCN Guidelines for Multiple Myeloma V.3.2016 – Web teleconference Interim Update on 12/14/15

Guideline Page and Request	Panel Discussion/References	Institution Vote			
		YES	NO	ABSTAIN	ABSENT
<p>MYEL-D (1 of 2) External request: Submission from Takeda Pharmaceutical Company Limited.</p> <p>Request the NCCN Multiple Myeloma Panel to review the data on the use of ixazomib in combination with lenalidomide and dexamethasone as first-line therapy for transplant-ineligible patients with multiple myeloma.</p>	<p>Based on the data in the noted reference and discussion, the panel added the combination ixazomib/lenalidomide/dexamethasone as a preferred regimen option for primary therapy.</p> <p>Kumar SK, Berdeja JG, Niesvizky R, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. <i>Lancet Oncol</i> 014;15(13):1503–12.</p>	15	0	0	11
<p>MYEL-D (1 of 2) Internal request: Change in category of bortezomib/len/dex for primary treatment of both transplant-eligible and ineligible from 2A to category 1.</p>	<p>Based on the data in the noted reference the NCCN Category of Evidence has been changed from a category 2A to a category 1.</p> <p>Durie B, Hoering A, Rajkumar SV, et al. Bortezomib, lenalidomide and dexamethasone Vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT): Results of the randomized phase III trial SWOG S0777. <i>Blood</i> 2015;126:25-25</p>	15	0	0	11
<p>MYEL-D (2 of 2) External request: Submission from: Bristol-Myers Squibb Company.</p> <p>Request the NCCN Multiple Myeloma Panel to consider recommending elotuzumab in combination with lenalidomide and dexamethasone in the NCCN Multiple Myeloma Guidelines as a Category 1 preferred regimen for previously treated multiple myeloma</p>	<p>Based on the data in the noted reference and discussion, the Panel added elotuzumab in combination with lenalidomide and dexamethasone as a preferred regimen option for previously treated multiple myeloma.</p> <p>Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. <i>N Engl J Med</i>. 2015. DOI: 10.1056/NEJMoa1505654.</p>	15	0	0	11
<p>MYEL-D (2 of 2) External request: Submission from: Bristol-Myers</p>	<p>Panel consensus supported not including this combination at this time.</p> <p>Jakubowiak A, Offidani M, Pegourie B, et al. A randomized, open-label,</p>	0	15	0	11

NCCN Guidelines for Multiple Myeloma V.3.2016 – Web teleconference Interim Update on 12/14/15

<p>Squibb Company.</p> <p>Request the NCCN Multiple Myeloma Panel to consider including elotuzumab in combination with bortezomib and dexamethasone as a treatment option for previously treated multiple myeloma.</p>	<p>Phase 2 study of bortezomib and dexamethasone with or without elotuzumab in patients with relapsed/refractory multiple myeloma. Oral presentation at: The 20th Congress of the European Hematology Association (EHA) Annual Meeting; June 11-14, 2015; Vienna, Austria</p>				
<p>MYEL-D (2 of 2) External request: Submission from Janssen Biotech, Inc.</p> <p>Request the NCCN Multiple Myeloma Panel to review the data for inclusion of daratumumab for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double refractory to a PI and immunomodulatory agent.</p>	<p>Based on the data in the noted reference and discussion, the panel added daratumumab as an option for the treatment of patients with relapsed/refractory multiple myeloma.</p> <p>Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. <i>N Engl J Med.</i> 2015;373(13)1207-1219.</p>	15	0	0	11
<p>MYEL-D (2 of 2) External request: Submission from Novartis Pharmaceuticals Corp.</p> <p>Request the NCCN Multiple Myeloma Panel to review data relating to treatment of relapse or progressive multiple myeloma with panobinostat in combination with carfilzomib.</p>	<p>Based on the data in the noted reference and discussion, the panel added panobinostat in combination with carfilzomib as a treatment option for patients with previously treated multiple myeloma.</p> <p>Berdeja JG, Heart LL, Mace JR, et al. Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma. <i>Haematologica.</i> 2015; 100(5): 670-676.</p>	15	0	0	11
<p>MYEL-D (2 of 2) External request: Submission from Takeda Pharmaceutical Company Limited.</p> <p>Request the NCCN Multiple Myeloma Panel to review the data</p>	<p>Based on the data in the noted reference and discussion, the panel added ixazomib/lenalidomide/dexamethasone as a preferred regimen option for previously treated multiple myeloma.</p> <p>Moreau P, Masszi T, Grzasko N, et al. Ixazomib, an investigational oral proteasome inhibitor (PI), in combination with lenalidomide and dexamethasone (IRd), significantly extends progression-free survival</p>	15	0	0	11

NCCN Guidelines for Multiple Myeloma V.3.2016 – Web teleconference Interim Update on 12/14/15

<p>on the use of ixazomib in combination with lenalidomide and dexamethasone as therapy for patients with previously treated multiple myeloma.</p>	<p>(PFS) for patients (Pts) with relapsed and/or refractory multiple myeloma (RRMM): The Phase 3 TOURMALINE-MM1 Study (NCT01564537). Blood 2015;126(21):abstract 727; data from ASH 2015 Annual Meeting abstract.</p>				
<p>MYEL-D (2 of 2) External request: Submission from Takeda Pharmaceutical Company Limited. Request the NCCN Multiple Myeloma Panel to review the data on the use of ixazomib as a single agent or in combination with dexamethasone as therapy for patients with previously treated multiple myeloma.</p>	<p>Based on the data in the noted references and discussion, the panel added ixazomib ± dexamethasone as a preferred regimen option for previously treated multiple myeloma.</p> <p>Kumar SK, LaPlant B, Roy V, et al. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer J 2015;5:e338.</p> <p>Kumar SK, Laplant BR, Reeder CB, et al. Randomized phase 2 trial of two different doses of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood 2015;126:3050-3050.</p>	<p>15</p>	<p>0</p>	<p>0</p>	<p>11</p>